Abstract (EN):
The present application discloses novel family of Tryptophanol-Derived Oxazoloisoindolinones for use in the treatment of p53 associated conditions, such as cancer. These compounds are p53 activators and may be used in pharmaceutical compositions, alone or in combination with other chemoterapeutic agents.
Idioma:
Inglês
Tipo (Avaliação Docente):
Científica
Notas:
Número de publicação WO2014207688 A1
Links Externos: Patentscope, Espacenet
Tipo de Licença: